Abraxane for Metastatic Pancreatic Cancer - Details


( Last Updated : October 8, 2014)
Generic Name:
Nab-paclitaxel
Project Status:
Complete
Therapeutic Area:
Metastatic Pancreatic Cancer
Manufacturer:
Celgene Inc.
Brand Name:
Abraxane
Project Line:
Reimbursement Review
Project Number:
PC0037-000
NOC Date:

Details


Strength:
100 mg/vial
Tumour Type:
Gastrointestinal
Indications:
Metastatic Pancreatic Cancer
Funding Request:
For the first line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.
Pre Noc Submission:
Yes
Sponsor:
Celgene Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Clarification:
A delay in the receipt of marketing authorization (NOC) from Health Canada has impacted the review timeline.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Clarification:
A delay in the receipt of marketing authorization (NOC) from Health Canada has impacted the review timeline.
Funding Request:
For the first line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.
pERC Meeting:
Final Recommendation:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.